Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa
- 1 July 2021
- journal article
- letter
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 46 (5), 936-938
- https://doi.org/10.1111/ced.14602
Abstract
Hidradenitis Suppurativa (HS) is a chronic relapsing inflammatory disease that results in painful, recurring subcutaneous nodules in skin folds and leads to a physical and psychosocial burden on patients. Current treatments are shifting towards biologics that target the exaggerated immune response. Unfortunately, even under optimal biologic therapy, some patients fail to respond. For example, about 50% of patients treated with adalimumab fail to respond (primary failure).1 Some initial responders lose efficacy over time (secondary failure). One factor that may lead to treatment failure is immunogenicity and anti‐drug antibodies (ADA). In phase 3 trials, at least one exposure to adalimumab resulted in overall ADA prevalence of 6.5% and prolonged exposure resulted in 10.1%. ADA presence is consistently associated with lower serum drug concentrations.2 ADA can occur with other biologic drugs however the relevance to HS management is unclear.3This publication has 6 references indexed in Scilit:
- Therapeutic drug monitoring of biologics in psoriasisBiologics: Targets and Therapy, 2019
- Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyJournal of the American Academy of Dermatology, 2019
- Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque PsoriasisJournal of Investigative Dermatology, 2018
- American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel DiseasesGastroenterology, 2017
- Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis SuppurativaClinical Pharmacokinetics, 2017
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnnals Of The Rheumatic Diseases, 2012